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ABSTRACT
The effects of glucocorticoids on the regulation of rat liver S-ad-
enosylmethionine synthetase were studied in vivo and in two culture
systems. Livers from adrenalectomized animals were examined for
enzyme activity, immunoreactive protein, and messenger RNA
(mRNA) content. All three parameters showed a similar trend, i.e.
they decreased 3-fold after adrenalectomy and increased over the
control values upon triamcinolone replacement. These results sug-
gested that glucocorticoid regulation of hepatic S-adenosylmethi-
onine synthetase was mediated at the mRNA level. Triamcinolone
and dexamethasone increased S-adenosylmethionine synthetase
mRNA content in a time- and dose-dependent manner in both rat
hepatoma H35 cells and primary cultures of adult rat hepatocytes.
The kinetics of mRNA induction were identical in both culture sys-
tems, indicating that the hormone-mediated response is independent
of the differentiated state of the cell. Insulin blocked the inducing
effect of glucocorticoids on S-adenosylmethionine synthetase mRNA
in a dose-dependent manner. On the other hand, the triamcinolone-
dependent increase in mRNA levels was completely abolished by
treatment with actinomycin D, whereas cycloheximide did not affect
this response. The transcription rate of the gene, as measured by
run-on assay, increased 3-fold after hormone addition. Transient
transfections of H35 cells with 1.4 kilobases of the 59-flanking region
of the hepatic S-adenosylmethionine synthetase gene fused to a lu-
ciferase reporter gene showed that promoter activity is also increased
3-fold after triamcinolone treatment, suggesting that this promoter
region contains the sequence elements necessary to confer glucocor-
ticoid responsiveness. In addition to the transcriptional control of the
hepatic S-adenosylmethionine synthetase gene, our results suggest
that glucocorticoids may be acting at a posttranscriptional level. (En-
docrinology 138: 1251–1258, 1997)
S-ADENOSYLMETHIONINE (AdoMet) synthetase (EC2.5.1.6) is a housekeeping enzyme that catalyzes the
only known route of biosynthesis of AdoMet in a reaction
that involves the transfer of the adenosyl moiety from ATP
to the sulfur atom of methionine (1). The relevance of this
reaction has been recently emphasized by the fact that
AdoMet synthetase has been found to be included in the
minimal set of functional gene products necessary for inde-
pendent life (2). This is due to the central position that
AdoMet occupies in cellular metabolism; it is the donor of
methyl groups for most of transmethylation reactions, which
are essential to maintain cellular structure and function, and
serves as the source of propylamine moieties for polyamine
biosynthesis (3, 4). In mammalian liver, this metabolite also
participates in the transsulfuration pathway (5), which leads
to the synthesis of compounds involved in maintaining the
normal redox potential, such as glutathione. Among mam-
malian tissues, liver exhibits the highest enzyme specific
activity, consistent with the fact that the majority of methi-
onine taken up from the diet is metabolized by this pathway
in this organ (6). Related to this, anAdoMet synthetase isoen-
zyme is selectively expressed in the liver, whereas in other
tissues, the so-called extrahepatic or kidney-type AdoMet
synthetase is present (reviewed in Refs. 7 and 8).
Over the past few years, much effort has been devoted to
study of the regulation of hepatic AdoMet synthetase under
various pathophysiological conditions. The specific activity
of the enzyme has been shown to be altered in response to
tissue damage, concomitantly with a severe impairment of
methionine metabolism. For instance, a marked reduction in
enzyme activity has been found in human alcoholic (9, 10),
biliary (11), and posthepatitic cirrhosis (9) as well as in dif-
ferent experimental models of liver injury (see Ref. 8 and
references therein). Various pieces of evidence have led to the
suggestion that the activity of the enzyme could be regulated
under these conditions by the oxidation state of its thiol
groups (12–15). The involvement of other possible regulatory
mechanism, such as the modulation of the messenger RNA
(mRNA) levels, has been also explored. Thus, in a rat model
of carbon tetrachloride-induced liver damage, despite the
marked reduction in enzyme activity, the levels of the cor-
responding mRNA have been found to be similar to those
detected in normal liver (16), a findingwhich agreeswith that
derived from the analysis of liver biopsies from alcoholic
cirrhotic patients (17). These results supported the idea that
the decrease in hepatic AdoMet synthetase activity observed
under several pathological situations was due to posttrans-
lational events rather than to a reduced expression of the
gene.
The activity of the enzyme has been also found to be
influenced by hormonal stimuli. In this regard, it was pre-
viously reported that hepatic AdoMet synthetase activity is
altered in adrenalectomized animals (18–20), suggesting a
role for glucocorticoids in its regulation. These hormones
account for pleitropic effects in liver, and its action on hepatic
AdoMet synthetase could be of major physiological rele-
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vance. However, the mechanisms underlying this regulation
remain unknown to date. The present work was undertaken
to investigate such mechanisms. Our results show that glu-
cocorticoids strongly up-regulate this enzyme both in vivo
and in hepatic cultured cells and have a direct effect on
enzyme gene expression. The physiological significance of
this regulation is further discussed.
Materials and Methods
Animals and in vivo procedures
Male Wistar rats, weighing 180–210 g, were maintained in temper-
ature-controlled rooms under 12-h light-dark cycles, with standard diet
provided ad libitum. Bilateral adrenalectomy or sham operation was
performed under ether anesthesia. Adrenalectomized animals received
0.9% NaCl in their drinking water. Triamcinolone (Sigma Chemical Co.,
St. Louis, MO; 5 mg/100 g BW) was injected ip at two consecutive 24-h
intervals, 7 days after adrenalectomy. Livers were freeze-clamped in
liquid nitrogen and stored at270 C before the extraction of proteins and
mRNA. All animal procedures were approved by the animal care and
use committee of our institution.
Isolation and culture of rat hepatocytes
Hepatocytes were isolated by the collagenase perfusion method (21)
with the modifications previously outlined (22). Only cell preparations
whose viability, estimated by the trypan blue exclusion test, was higher
than 90% were used. Hepatocytes were seeded at a density of 5 3 104
cells/cm2 in RPMI supplemented with 10% FCS, 2 mm glutamine, and
antibiotics at 37 C in an humidified atmosphere of 5%CO2-95% air. After
a 4-h incubation period, the medium was replaced by serum-free me-
dium and incubated for 16 h. Then, treatments with triamcinolone,
dexamethasone, or vehicle (methanol) at the indicated concentrations
were started.
Cell culture
Rat hepatomaH35 cells were grown to 70–80% confluence in DMEM
supplemented with 10% FCS. The cells were changed to a medium
containing 0.5% FCS 24 h before the addition of hormones or vehicle. For
time-course experiments, cells were harvested at the indicated times
after the addition of 100 nm triamcinolone or dexamethasone. Triam-
cinolone and dexamethasone were dissolved in methanol and ethanol,
respectively. When required, actinomycin D and cycloheximide (Sigma)
were used at concentrations of 5 and 10 mg/ml, respectively. Human
insulin (Novo Nordisk, Copenhagen, Denmark) was used at the indi-
cated concentrations.
Determination of AdoMet synthetase activity
For determination of AdoMet synthetase activity, liver portions were
homogenized at 4 C in 4 vol 10 mm Tris-HCl pH 7.5, containing 0.3 m
sucrose, 0.1% b-mercaptoethanol, 1 mm benzamidine, and 0.1 mm phe-
nylmethylsulfonylfluoride. The homogenate was centrifuged at 4 C for
20 min at 10,000 3 g, and the supernatant was again centrifuged for 60
min at 100,000 3 g. AdoMet synthetase activity was assayed in this last
supernatant as previously described (23). Samples of 160 ml were incu-
bated with 90 ml of a reaction mixture containing 75 mm Tris-HCl (pH
8.0), 250 mm KCl, 9 mmMgCl2, 10 mm dithiothreitol, 5 mmmethionine,
and 5 mm [2-3H]ATP (4Ci/mol). The incubation was carried out for 30
min at 37 C and was stopped by the addition of 4–5 ml distilled water.
The samples were immediately loaded on 1-ml cation exchanger AG
50W-X4 columns (Bio-Rad Laboratories, Richmond, CA) equilibrated in
water. The columns were washed with water (20 ml), and [3H]AdoMet
was then eluted with 4 ml 3m ammonium hydroxide. Radioactivity was
determined in the presence of 1 ml glacial acetic acid and 10 ml scin-
tillation liquid (Optiphase HiSafe 3, Pharmacia, Uppsala, Sweden).
Northern blot analysis
Total RNA was isolated by the guanidinium isothiocyanate method
(24), size-fractionated on 1% agarose denaturing gels, and transferred to
Nytranmembranes (Schleicher and Schuell, Keene,NH). The filterswere
hybridized with an EcoRI fragment of plasmid pSSRL, containing 2.2
kilobases (kb) of rat liver AdoMet synthetase complementary DNA
(cDNA) (25). A cDNA for the 18S ribosomal RNA inserted into plasmid
pBR322 and/or a rat glyceraldehyde phosphate dehydrogenase
(GAPDH) cDNA (26) (provided by Dr. R. Wu) were used for normal-
ization. The probeswere randomprimed labeledwith [a-32P]deoxy-CTP
using the Megaprime labeling kit (Amersham, Little Chalfont, UK).
Prehybridization and hybridization were carried out as previously de-
scribed (27). The filters were scanned on a Molecular Imager GS-250
(Bio-Rad Laboratories, Richmond, CA), and quantitative analysis of the
autoradiograms was carried out running the Phosphor analyst software
(Bio-Rad Laboratories, Richmond, CA).
Western blot analysis
Samples from rat liver or H35 cells were homogenized in 10 mm
Tris-HCl, pH 7.5–0.3 m sucrose buffer, as indicated, for determination
of AdoMet synthetase activity. Forty micrograms of proteins from the
cytosolic fractions were fractionated by 10% SDS-PAGE gels and elec-
trotransferred to nitrocellulose membranes using 20 mm Tris-HCl pH
7.5, containing 20% methanol. After transfer, the blots were incubated
consecutively with a rabbit antiserum raised against purified rat liver-
specific AdoMet synthetase (28) (dilution, 1:10000) and horseradish per-
oxidase-conjugated antirabbit IgG. Blots were developed with ECL de-
tection reagents (DuPont-New England Nuclear, Boston, MA),
following the manufacturer’s instructions. The immunoblot bands were
measured bydensitometric analysis of the autoradiographs. The amount
of the sample used and the time of exposure to the x-ray filmwere chosen
to give a linear response.
Nuclear run-on analysis
Nuclei from H35 cells untreated or treated for 1 and 6 h with 100 nm
triamcinolone were isolated as previously described (29). For each prep-
aration of nuclei, three 10-cm dishes (1.5 3 107 cells) were used. Nuclear
suspensions (100 ml) were incubated with 0.5 mm each of CTP, ATP, and
GTP and with 200 mCi [a-32P]UTP (3000 Ci/mmol; DuPont-New
England Nuclear). The 32P-labeled RNA was isolated after deoxyribo-
nuclease I and proteinase K treatments by phenol-chloroform extraction
and ethanol precipitation; then it was further purified by Sephadex G-50
chromatography. Equal amounts (107 cpm/ml) of labeled nuclear RNA
were hybridized at 42 C for 72 h to 5 mg linearized plasmid DNAs
immobilized on Nytran membranes. The plasmids used were pSSRL
(25), plasmid pPCK10 (30) (provided by Dr. R. W. Hanson), containing
a 2.6-kb cDNA for rat cytosolic phosphoenolpyruvate carboxykinase
(PEPCK) cDNA, a rat GAPDH cDNA (26), and pUC18 (for background
control). After washing, the filters were exposed to a phosphorimaging
screen (Bio-Rad) for quantification of the radioactive transcripts. Data
were normalized to transcription of the GAPDH gene.
Transient transfection analysis
A rat genomic DNA fragment containing 1.4 kb of a recently cloned
rat liver-specific AdoMet synthetase promoter (L. Alvarez, E. Sa´nchez-
Go´ngora, J. Mingorance, B. Gil,M. A. Pajares, and J.M.Mato,manuscript
in preparation) was used to drive expression of the luciferase gene in the
promoterless vector pXP1 (31) (kindly provided by Dr. S. K. Nordeen).
The b-galactosidase expression vector pCH110 (Pharmacia) was used as
an internal standard of transfection efficiency. H35 cells were cultured
in DMEM supplementedwith 10% FCS and plated at approximately 33
105 cells/60-mm culture dish 24 h before transfections. The cells were
transfected by the calcium phosphate precipitation method (32) with
either 15 mg of the AdoMet synthetase promoter-luciferase construct or
pXP1 vector and 5 mg of the pCH110 plasmid. After 18 h, the DNA
precipitates were rinsed twice with PBS, and cells were incubated in
DMEM supplemented with 0.5% FCS and treated for 24 h with or
without 100 nm triamcinolone. The cells were harvested in reporter lysis
buffer (Promega, Madison, WI), following the manufacturer’s instruc-
tions and the lysate was spun in a microcentrifuge for 15 sec. Luciferase
and b-galactosidase activities were determined as previously described
(32, 33). All transfections were conducted in triplicate, using at least two
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different batches of each plasmid. The activities reported are averaged
from three independent experiments.
Results
Effects of adrenalectomy and triamcinolone replacement on
hepatic AdoMet synthetase activity, immunoreactive protein,
and mRNA levels
The regulation of hepatic AdoMet synthetase by glu-
cocorticoids was first examined in vivo in adrenalecto-
mized rats. In liver from adrenalectomized animals, the
specific activity of the enzyme, assayed at saturating con-
centrations of the substrates, ATP and methionine, was
determined to be 48 6 8 pmol/minzmg protein, signifi-
cantly lower than that obtained in liver from sham-oper-
ated rats (158 6 12 pmol/minzmg protein; Fig. 1A). Ad-
ministration of the synthetic glucocorticoid triamcinolone
(5 mg/100 g BW; two consecutive doses at daily intervals)
to adrenalectomized rats restored AdoMet synthetase ac-
tivity, which reached a value of 196 6 15 pmol/minzmg
protein. To investigate whether these changes in enzyme
activity were associated with relative changes in the
amount of the corresponding protein, the same cytosolic
extracts used for determination of enzyme activity were
subjected to immunoblotting. As shown in Fig. 1B, a
marked reduction in immunoreactive protein was ob-
served in liver extracts from adrenalectomized rats compared
to that in liver extracts from sham-operated controls. Triam-
cinolone replacement increased the levels of protein over the
values detected in the sham group. Thus, changes in AdoMet
synthetase activity with adrenalectomy and triamcinolone re-
placement appear to reflect changes in the corresponding pro-
tein. To define further the molecular basis for AdoMet syn-
thetase regulation, total RNA was isolated and subjected to
Northern blot analysis. The abundance of the AdoMet syn-
thetasemRNAchanged inasimilar fashionas theprotein.Thus,
a 3-fold reduction in hepatic AdoMet synthetase mRNA levels
was detected in adrenalectomized rats compared with sham-
operated controls; again, this effect was prevented by hormone
treatment (Fig. 1C). Adrenalectomy and triamcinolone replace-
ment had no effect on the levels of 18S ribosomal RNA (Fig. 1C)
or GAPDH mRNA (data not shown). Overall, there was a
strong correlation between the activity values and protein and
mRNA contents, suggesting an in vivo regulatory mechanism
acting primarily at the mRNA level.
Up-regulation of hepatic AdoMet synthetase by
glucocorticoids in rat hepatoma H35 cells
To specifically study the effect of glucocorticoids on the
regulation of this enzyme, two culture systems, namely rat
hepatoma H35 cells and primary cultures of adult rat hepa-
tocytes, were used. Initially, H35 cells were tested for
AdoMet synthetasemRNA expression after stimulationwith
triamcinolone. As shown in Fig. 2A, triamcinolone signifi-
cantly up-regulated AdoMet synthetase mRNA expression
FIG. 1. Effect of adrenalectomy and tri-
amcinolone replacement on rat liver
AdoMet synthetase activity, protein,
and mRNA levels. Sham-operated or
adrenalectomized (ADX) animals were
either injected with 0.9% saline or
treated with triamcinolone (50 mg/kg,
ip) for 48 h. A, AdoMet synthetase ac-
tivity, assayed at saturating concentra-
tions of the substrates, as described un-
derMaterials and Methods. B, Western
blot analysis. Equal amounts of cytoso-
lic proteins (30 mg) from the same sam-
ples used for determination of enzyme
activity were fractionated by 10% SDS-
PAGE and subjected to immunoblot
analysis with an antibody raised
against rat liverAdoMet synthetase (di-
lution, 1:10,000). C, Northern blot anal-
ysis, performed with 30 mg total RNA.
Filters were hybridized to a 32P-labeled
rat liver AdoMet synthetase cDNA or to
a rat 18S ribosomal RNA probe. Cor-
rected densitometric quantitation is
shown. Values are expressed as the
mean 6 SEM of four animals in each of
the groups. *, P , 0.01 vs. sham group.
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in a time-dependent manner. The mRNA levels of hepatic
AdoMet synthetase detected in this cell line were low in the
absence of hormone, but began to increase 2 h after the
addition of triamcinolone and reached a maximum at 24 h
(14-fold induction), decreasing slightly at 48 h. The levels of
immunoreactive protein followed a trend similar to mRNA
expression (Fig. 2B), but a delay was detected, reaching a
plateau at 36 h (Fig. 2C). Identical resultswere obtainedwhen
another synthetic glucocorticoid, dexamethasone, was used
(data not shown). Thus, as observed in adrenalectomized
animals, the expression profile of immunoreactive protein
paralleled that for the mRNA, further indicating that glu-
cocorticoidsmodulate AdoMet synthetase expression by act-
ing mainly at the mRNA level. Therefore, subsequent ex-
periments were focused on mRNA expression.
The triamcinolone-mediated induction of AdoMet syn-
thetase mRNA was dose dependent. As shown in Fig. 3,
AdoMet synthetase mRNA expression gradually increased
with the triamcinolone concentration, yielding a sigmoidal
curve with a half-maximal mRNA induction at a concentra-
tion between 1029–1028 m. The levels of corticosterone,
which is the natural glucocorticoid in rat and is an order of
magnitude less potent than synthetic glucocorticoids, show
a daily rhythm, ranging from 1027–1026 m (34). Therefore, it
can be concluded that glucocorticoids control the expression
of the hepatic AdoMet synthetase gene in their physiological
concentration range.
Effects of triamcinolone on hepatic AdoMet synthetase
mRNA in primary cultures of adult rat hepatocytes
The regulation of AdoMet synthetase gene expressionwas
also examined in primary cultures of hepatocytes, because
they resemble the normal functions of liver cells in vivomore
closely than hepatoma cells. In this case, the steady state
levels of hepatic AdoMet synthetase mRNA detected were
much higher than those in the rat hepatoma cell line. Re-
gardless of this, triamcinolone increased mRNA content in a
time- and dose-dependent manner to a similar extent as
observed in H35 cells (Fig. 4).
Glucocorticoid-insulin antagonism in the regulation of
AdoMet synthetase mRNA
Previous studies have shown that hepatic AdoMet syn-
thetase activity is increased in alloxan diabetic rats (19, 35,
36). Based on this and the fact that the actions of glucocor-
ticoids in the regulation of various metabolic pathways are
opposed by insulin, we next examined whether insulin was
able to antagonize the stimulatory effect of triamcinolone on
AdoMet synthetase mRNA expression. For this purpose, in-
sulin at different concentrations was added to rat hepatoma
H35 cells simultaneously with a fixed dose of triamcinolone
(100 nm), which by itself caused a maximal induction of the
mRNA. Under these conditions, glucocorticoid stimulation
was inhibited about 50% by an insulin concentration of 1028
m and was totally suppressed by 1026 m (Fig. 5). In parallel
experiments, insulin alone had negligible effects on hepatic
AdoMet synthetase mRNA expression (data not shown).
Effects of cycloheximide and actinomycin D on the
triamcinolone-dependent increase in AdoMet synthetase
mRNA
To determine whether the effect of triamcinolone on
AdoMet synthetase transcripts was dependent on protein
synthesis, cultures of H35 cells were treated with 100 nm
triamcinolone in the presence or absence of 10 mg/ml cy-
cloheximide. After 8 h of treatment, the induction of AdoMet
synthetase mRNA was not inhibited by cycloheximide (Fig.
6), indicating that on-going protein synthesis is not required
for triamcinolone-dependent AdoMet synthetase mRNA in-
duction. This result suggests that preexisting glucocorticoid
receptors mediated the triamcinolone up-regulation of
AdoMet synthetase mRNA. On the other hand, to determine
whether the glucocorticoid effect on hepatic AdoMet syn-
thetase expression was at the transcriptional level, cultures
of H35 cells were treated for 8 h with 100 nm triamcinolone
in the presence of the transcriptional inhibitor actinomycin
D at a concentration of 5 mg/ml. As shown in Fig. 6, this
treatment prevented stimulation by triamcinolone, suggest-
ing that AdoMet synthetase mRNA induction by glucocor-
ticoids is transcriptionally regulated.
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FIG. 2. Time course of hepatic AdoMet synthetase mRNA and im-
munoreactive protein induction in rat hepatomaH35 cells in response
to triamcinolone. H35 cells were treated with 100 nM triamcinolone,
and total RNA was extracted at the indicated times. A, Northern blot
analyses, performed with 30 mg total RNA. Filters were hybridized to
a 32P-labeled rat hepatic AdoMet synthetase or to a rat 18S ribosomal
RNA probe. B, For Western blot, equal amounts of cytosolic proteins
(30 mg) were fractionated by 10% SDS-PAGE and subjected to im-
munoblot analysis with an antibody raised against the liver-specific
AdoMet synthetase (dilution, 1:10,000).Densitometric quantitation is
shown below. Immunoreactive protein and mRNA levels are ex-
pressed relative to the maximal value, which was taken as 10.
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Transcriptional regulation of the hepatic AdoMet synthetase
gene by triamcinolone
To determine more directly whether glucocorticoids con-
trol the transcription of the hepatic AdoMet synthetase gene,
nuclear run-on assays were performed on nuclei from H35
cells treated with 100 nm triamcinolone for 1 or 6 h. The
behavior of the gene coding for cytosolic PEPCK was simul-
taneously tested as an internal standard of enzymes tran-
scriptionallymodulated by glucocorticoids in hepatoma cells
(37). As illustrated in Fig. 7A, a significant increase in the
transcriptional activities of both PEPCK and hepatic AdoMet
synthetase genes was achieved after triamcinolone stimula-
tion. Quantification of the data from three independent ex-
periments revealed that the relative rate of transcription of
the hepatic AdoMet synthetase gene, after normalization to
GAPDH transcription rate, was increased about 2.8-fold 1 h
after triamcinolone addition and 3.2 fold at 6 h.
To further characterize the effects of triamcinolone on tran-
scription of the AdoMet synthetase gene, H35 cells were
transiently transfected with a construct containing a 1.4-kb
fragment of the rat liver-specific AdoMet synthetase pro-
moter fused to the luciferase reporter gene. Treatment of
transfected cells with 100 nm triamcinolome for 18 h pro-
duced a 3-fold increase in luciferase activity (Fig. 7B), which
agrees with the results of the run-on analysis.
Effects of triamcinolone on the turnover of hepatic AdoMet
synthetase mRNA
We also evaluated whether glucocorticoids alter the turn-
over of hepatic AdoMet synthetase mRNA. The decay of
AdoMet synthetase mRNA was followed in H35 cells that
had been treated with 100 nm triamcinolone. Sixteen hours
after triamcinolone addition, the hormone was either main-
tained or removed, and the cells were incubated for addi-
tional times in the presence or absence of actinomycin D (Fig.
8). When triamcinolone was withdrawn and the cells were
cultured in the absence of the transcription inhibitor, the
mRNA decayed with a first order kinetics, exhibiting a half-
life of about 7 h. The rate of decay of the mRNA was much
slower after actinomycin D addition either in the continued
presence or after withdrawal of triamcinolone.
Discussion
An important physiological action of glucocorticoids is the
control of the expression of hepatic genes encoding regula-
tory enzymes of intermediary metabolism. Some of these
enzymes are involved in hepatic amino acid metabolism,
such as tyrosine aminotransferase (38) and the urea cycle
enzymes (39). In the present report, we show that these
hormones strictly regulate the liver-specific AdoMet syn-
thetase, the enzyme that catalyzes the preferred pathway for
methionine breakdown. Previous studies had shown that
adrenalectomy reduces AdoMet synthetase activity in rat
liver, and cortisone administration can effectively prevent
this effect (20). Our results reveal that after adrenalectomy
and triamcinolone replacement, changes in the specific ac-
tivity of the enzyme correlate with changes in immunore-
active protein andmRNA contents, therefore suggesting that
in vivo regulation of hepatic AdoMet synthetase by glucocor-
ticoids is mediated at the mRNA level. A direct and specific
action of glucocorticoids on the enzyme gene expression has
been demonstrated by using two cell culture systems, rat
hepatoma H35 cells and primary cultures of adult rat hepa-
tocytes. It is noteworthy that after triamcinolone stimulation,
the response and kinetics of hepatic AdoMet synthetase
mRNA expression were similar in both systems despite the
fact that basal levels of the mRNAwere low in the hepatoma
cells. This interesting finding reveals that the machinery in-
volved in glucocorticoid-mediated regulation of AdoMet
synthetase gene expression is conserved in a dedifferentiated
cell line such as rat hepatoma H35. Also consistent with the
results derived from in vivo studies, the increase in mRNA
content was paralleled by increased levels of immunoreac-
tive AdoMet synthetase in cultured cells. Although the in-
duction profiles of hepatic AdoMet synthetase mRNA and
protein were almost identical, a pronounced delay in the
accumulation of protein with respect to the mRNA was de-
tected. This effect has been evidenced for a variety of en-
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FIG. 3. Triamcinolone up-regulates AdoMet synthetase mRNA in a
dose-dependent manner. H35 cells were incubated for 16 h with in-
creasing concentrations of triamcinolone. Northern blot was per-
formed as detailed inMaterials and Methods. A semilogarithmic plot
showing normalized hepatic AdoMet synthetase mRNA levels vs.
hormone concentration is depicted below.
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zymes (40) and could be explained by the time required for
AdoMet synthetase translation from mRNA to protein.
The finding that glucocorticoid-mediated up-regulation of
hepatic AdoMet synthetase mRNA expression is antagonized
by insulin might be related to the fact that the action of glu-
cocorticoids in the regulationof carbohydrate,protein, and lipid
metabolism is commonly opposed by insulin. In this context, a
negative effect of insulin onglucocorticoid-inducedmRNAlev-
els has been reported for several proteins involved in hepatic
metabolism, such as tyrosine aminotransferase (41), PEPCK
(37), or IGF-binding protein-1 (42). The mechanisms by which
insulin antagonizes glucocorticoid regulation of gene expres-
sion are still poorly understood. Recent reports have provided
evidence that in hepatic cells, insulin may act indirectly by
interferingwith transcription factorsnecessary for theglucocor-
ticoid response (43–45). Other possible mechanisms could be
related to the ability of the insulin-degrading enzyme to interact
with the glucocorticoid receptor, which has been suggested to
potentially couple insulin and steroid hormone signaling path-
ways (46).
Run-on transcription assays with isolated nuclei have pro-
vided direct evidence for a transcriptional activation of the
hepatic AdoMet synthetase gene by glucocorticoids. In keep-
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FIG. 4. Up-regulation of hepatic
AdoMet synthetasemRNA by triamcin-
olone in primary cultures of adult rat
hepatocytes. A, Time course of hepatic
AdoMet synthetase mRNA induction in
response to triamcinolone. Hepatocytes
were isolated following the classical col-
lagenase perfusion method, cultured as
detailed inMaterials and Methods, and
treated with 100 nM triamcinolone.
RNA was extracted at the indicated
times. Northern blot analysis was per-
formed with 20 mg total RNA. Filters
were hybridized to a 32P-labeled rat he-
patic AdoMet synthetase or to 18S ri-
bosomal RNA probe. The corrected den-
sitometric quantitation is shown below.
ThemRNA levels are expressed relative
to the value at time zero, which was
taken as 1. B, Dose-dependent effect of
triamcinolone on AdoMet synthetase
mRNA. Primary cultures of rat hepato-
cytes were incubated for 12 h with in-
creasing concentrations of triamcino-
lone. A semilogarithmic plot showing
normalized hepatic AdoMet synthetase
mRNA levels vs. hormone concentra-
tion is shown below. Each autoradio-
gram presented is representative of
three independent experiments.
18S  rRNA
AdoMet 
synthetase
 mRNA
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Triamcinolone + + + + +++ -+
FIG. 5. Inhibition by insulin of the triamcinolone-induced increase of
AdoMet synthetase mRNA levels. H35 cells were incubated for 24 h
with 100 nM triamcinolone and the indicated concentrations of insu-
lin. Hormones were added alone or simultaneously as indicated.
Northern analysis was performed with 30 mg total RNA.
Control CHX ActD
Triamcinolone
(100 nM) + + +- - -
18S rRNA
AdoMet 
synthetase
 mRNA
FIG. 6. Actinomycin and cycloheximide effects on hepatic AdoMet
synthetase inducibility by triamcinolone. H35 hepatoma cells were
incubated for 8 h in the presence of 100 nM triamcinolone or vehicle.
When indicated, either actinomycin at 5 mg/ml or cycloheximide at 10
mg/ml was added to the culture medium simultaneously with the
hormone. Northern blot analysis was performed with 30 mg total
RNA. Hybridization with 18S ribosomal RNA probe is shown below.
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ing with this, the activity of the promoter was also induced
to a comparable level upon hormone stimulation, as deduced
from the transient transfection assays of reporter plasmids
containing 1.4 kb of the 59-flanking region of the rat liver
AdoMet synthetase gene. Therefore, it can be concluded that
the functional sequence elements conferring glucocorticoid
inducibility are present in this promoter region. In this re-
gard, it is interesting to note that it contains four putative
GREs (Alvarez, L., G. Sanchez-Go´ngora, J. Mingorance, B.
Gil, M. A. Pajares, manuscript in preparation; database ac-
cession number X80270). Further studies are required to ver-
ify whether these elements, either alone or in a combined
fashion, are mediating the glucocorticoid responsiveness of
the rat hepatic AdoMet synthetase gene.
Although glucocorticoids are primarily considered to
function by changing the rate of transcription of the target
genes (47, 48), they have been reported to also modulate
specific mRNA levels at the posttranscriptional level, includ-
ing alteration of mRNA stability (49, 50) and stimulation of
transport from the nucleus to cytoplasm (51). Such combined
actions, which can lead to more rapid and more marked
shifts in the expression of particular genes, also appear to
apply to the regulation of rat hepatic AdoMet synthetase, as
the 3-fold enhancement of the gene transcription rate does
not quantitatively match the 14-fold increase in mRNA con-
tent. Thus, although the action of glucocorticoids onAdoMet
synthetase gene expression is clearly a direct one, a second
factor may be required to sustain the hormonal effect. This
is consistent with the results derived from the mRNA turn-
over studies. In contrast with the disappearance of the
AdoMet synthetase mRNA after removal of triamcinolone,
its rate of decay after addition of the transcriptional inhibitor
actinomycin D was much slower, raising the possibility that
a short lived factor may be involved in the turnover process.
A similar suggestion has been derived from a number of
studies of various mRNAs in different cell types (22, 52–54).
AdoMet synthetase plays a crucial role in hepatic metabo-
lism, processingmost of the methionine taken up from the diet
and providing key metabolites for the cell. Therefore, the glu-
cocorticoid-mediated regulation of this enzyme could be a fac-
tor of major physiological significance, especially in those sit-
uations when the levels of these hormones are high, such as in
stress conditions or during the peak of the glucocorticoid cir-
cadian rhythm. On the other hand, it should bementioned that
glucocorticoids are used as therapeutic agents in alcoholic liver
cirrhosis. Interestingly, AdoMet synthetase activity has been
reported to be seriously reduced in such a liver disorder (9, 10).
Furthermore, it has been shown that long term consumption of
ethanol in baboons leads to a depletion of AdoMet levels, and
administration of this metabolite attenuates ethanol-induced
liver damage (55). Therefore, it is tempting to speculate that at
least some of the beneficial effects of glucocorticoids in liver
cirrhosis could be due to a direct stimulation of AdoMet syn-
thetase, which, in turn, would increase the availability of
AdoMet. Inkeepingwith this, thedataprovidedhere couldalso
offer new insights into the mechanisms by which glucocorti-
coids exert therapeutic effects in alcohol-induced liver damage.
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FIG. 7. Effects of glucocorticoids on rat liver AdoMet synthetase gene
transcription. A, Nuclear run-on analysis of the hepatic AdoMet syn-
thetase transcription rate after triamcinolone treatment. The tran-
scription run-on assay was carried out with nuclei isolated from H35
cells untreated or treated for 1 and 6 h with 100 nM triamcinolone.
PEPCK and GAPDH transcription rates were tested simultaneously.
The histogram shows a quantification of the AdoMet synthetase tran-
scription rate normalized to that one of GAPDH. B, Effects of glu-
cocorticoids on rat liver AdoMet synthetase gene promoter. Fifteen
micrograms of AdoMet synthetase-luciferase fusion construct or the
vector alone were transfected into H35 cells in the presence of 5 mg
of an internal standard, Rous sarcoma virus-b-galactosidase. Cells
were incubated with or without 100 nM triamcinolone 24 h before
reporter assays. Luciferase activities were normalized to b-galacto-
sidase expression. Values are expressed as the mean 6 SEM of three
separate experiments.
FIG. 8. Time course of hepatic AdoMet synthetasemRNA decay after
triamcinolone removal or after the addition of actinomycin D. H35 rat
hepatoma cells were cultured in the presence of 100 nM triamcinolone
for 16 h before deinduction. Triamcinolone was withdrawn by wash-
ing the monolayer three times with PBS, and cells were incubated for
additional times. In another set of experiments, actinomycin D (5
mg/ml) was added after hormone induction, and cells were then in-
cubated in the presence or absence of triamcinolone. Cells were har-
vested at the indicated times, and total RNA was extracted. Data are
plotted as a percentage of the AdoMet synthetase mRNA content
before deinduction. A representative result from three independent
experiments is shown.
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